Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price Target & Predictions
TEVA Stock Forecast
Teva Pharmaceutical Industries stock forecast is as follows: an average price target of $19.17 (represents a 7.39% upside from TEVA’s last price of $17.85) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
TEVA Price Target
The average price target for Teva Pharmaceutical Industries (TEVA) is $19.17 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $10.00. This represents a potential 7.39% upside from TEVA's last price of $17.85.
TEVA Analyst Ratings
According to 8 Wall Street analysts, Teva Pharmaceutical Industries's rating consensus is 'Buy'. The analyst rating breakdown for TEVA stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 1 'Hold' (12.50%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Teva Pharmaceutical Industries Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Ashwani Verma | UBS | $26.00 | $18.43 | 41.11% | 45.66% |
| Aug 28, 2024 | David Amsellem | Piper Sandler | $23.00 | $18.61 | 23.56% | 28.85% |
| Aug 01, 2024 | Balaji Prasad | Barclays | $22.00 | $17.43 | 26.22% | 23.25% |
| Jul 10, 2024 | Jasper Hellweg | Argus Research | $20.00 | $15.81 | 26.50% | 12.04% |
| Jul 10, 2024 | Ashwani Verma | UBS | $24.00 | $15.81 | 51.80% | 34.45% |
| Jun 05, 2024 | Balaji Prasad | Barclays | $21.00 | $16.63 | 26.28% | 17.65% |
| May 23, 2024 | Balaji Prasad | Barclays | $20.00 | $16.76 | 19.33% | 12.04% |
| May 13, 2024 | David Amsellem | Piper Sandler | $20.00 | $16.89 | 18.38% | 12.04% |
| Feb 12, 2024 | David Amsellem | Piper Sandler | $19.00 | $12.01 | 58.20% | 6.44% |
| Jan 23, 2024 | Glen Santangelo | Jefferies | $14.00 | $11.99 | 16.76% | -21.57% |
The latest Teva Pharmaceutical Industries stock forecast, released on Sep 03, 2024 by Ashwani Verma from UBS, set a price target of $26.00, which represents a 41.11% increase from the stock price at the time of the forecast ($18.43), and a 45.66% increase from TEVA last price ($17.85).
Teva Pharmaceutical Industries Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 5 | 10 |
| Avg Price Target | $24.50 | $23.00 | $20.90 |
| Last Closing Price | $17.85 | $17.85 | $17.85 |
| Upside/Downside | 37.25% | 28.85% | 17.09% |
In the current month, the average price target of Teva Pharmaceutical Industries stock is $24.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 37.25% increase as opposed to Teva Pharmaceutical Industries's last price of $17.85. This month's average price target is up 6.52% compared to last quarter, and up 17.22% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Jefferies | Buy | Buy | Hold |
| Sep 03, 2024 | UBS | Buy | Buy | Hold |
| Aug 28, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 01, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 10, 2024 | UBS | Buy | Buy | Hold |
| Jun 27, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 05, 2024 | Barclays | Overweight | Overweight | Hold |
| May 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 09, 2024 | Bank of America Securities | Buy | Buy | Hold |
Teva Pharmaceutical Industries's last stock rating was published by Jefferies on Sep 09, 2024. The company gave TEVA a "Buy" rating, the same as its previous rate.
Teva Pharmaceutical Industries Financial Forecast
Teva Pharmaceutical Industries Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $4.46B | $3.85B | $3.88B | $3.66B | $3.88B | $3.60B | - | $3.66B | $4.10B | $3.89B | $3.91B | $3.98B | $4.45B | $3.98B | $3.87B | $4.36B | $3.99B | $4.26B | $4.34B | $4.29B | $4.56B | $4.53B |
| Avg Forecast | $4.36B | $4.29B | $4.26B | $3.86B | $4.13B | $4.13B | $4.06B | $3.73B | $4.03B | $3.73B | $3.71B | $3.62B | $3.89B | $3.84B | $3.78B | $3.74B | $4.28B | $4.03B | $4.02B | $4.02B | $4.37B | $4.07B | $3.93B | $4.15B | $4.35B | $4.24B | $4.25B | $4.38B | $4.65B | $3.60B |
| High Forecast | $4.41B | $4.34B | $4.31B | $3.90B | $4.18B | $4.20B | $4.10B | $3.77B | $4.08B | $3.81B | $3.76B | $3.66B | $3.93B | $3.88B | $3.78B | $3.82B | $4.38B | $4.12B | $4.11B | $4.12B | $4.47B | $4.16B | $4.02B | $4.25B | $4.45B | $4.33B | $4.34B | $4.48B | $5.57B | $4.32B |
| Low Forecast | $4.26B | $4.19B | $4.16B | $3.77B | $4.04B | $4.01B | $3.96B | $3.65B | $3.93B | $3.59B | $3.63B | $3.54B | $3.80B | $3.75B | $3.78B | $3.64B | $4.17B | $3.93B | $3.92B | $3.92B | $4.26B | $3.97B | $3.83B | $4.05B | $4.24B | $4.13B | $4.14B | $4.27B | $3.72B | $2.88B |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | 1.11% | 1.03% | 1.04% | 1.01% | 1.00% | 0.94% | - | 0.98% | 0.96% | 0.96% | 0.97% | 0.99% | 1.02% | 0.98% | 0.98% | 1.05% | 0.92% | 1.01% | 1.02% | 0.98% | 0.98% | 1.26% |
Teva Pharmaceutical Industries's average Quarter revenue forecast for Mar 24 based on 3 analysts is $3.73B, with a low forecast of $3.65B, and a high forecast of $3.77B. TEVA's average Quarter revenue forecast represents a -16.27% decrease compared to the company's last Quarter revenue of $4.46B (Dec 23).
Teva Pharmaceutical Industries EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | $755.00M | $1.04B | $979.00M | $813.00M | $1.05B | $993.00M | - | $1.01B | $1.09B | $1.04B | $1.09B | $1.13B | $1.12B | $1.08B | $1.07B | $1.33B | $1.12B | $1.11B | $1.13B | $1.08B | $971.00M | $1.12B |
| Avg Forecast | $1.13B | $1.11B | $1.10B | $1.00B | $1.07B | $1.07B | $1.05B | $390.83M | $1.04B | $967.89M | $963.15M | $355.30M | $1.01B | $1.13B | $978.91M | $323.00M | $210.26M | $1.03B | $819.09M | $750.42M | $848.83M | $-3.83B | $616.81M | $450.61M | $641.31M | $326.44M | $-200.84M | $545.52M | $-2.50B | $347.41M |
| High Forecast | $1.14B | $1.13B | $1.12B | $1.01B | $1.08B | $1.09B | $1.06B | $469.00M | $1.06B | $988.40M | $974.27M | $426.36M | $1.02B | $1.36B | $978.91M | $387.60M | $252.31M | $1.23B | $982.91M | $900.51M | $1.02B | $-3.07B | $740.17M | $540.73M | $769.57M | $391.73M | $-160.67M | $654.62M | $-2.00B | $416.89M |
| Low Forecast | $1.10B | $1.09B | $1.08B | $977.42M | $1.05B | $1.04B | $1.03B | $312.66M | $1.02B | $929.72M | $941.02M | $284.24M | $984.99M | $904.05M | $978.91M | $258.40M | $168.21M | $821.87M | $655.27M | $600.34M | $679.06M | $-4.60B | $493.45M | $360.49M | $513.05M | $261.15M | $-241.01M | $436.41M | $-3.01B | $277.93M |
| Surprise % | - | - | - | - | - | - | - | - | 0.72% | 1.08% | 1.02% | 2.29% | 1.04% | 0.88% | - | 3.13% | 5.18% | 1.01% | 1.33% | 1.51% | 1.31% | -0.28% | 1.74% | 2.96% | 1.75% | 3.40% | -5.62% | 1.99% | -0.39% | 3.22% |
3 analysts predict TEVA's average Quarter EBITDA for Mar 24 to be $390.83M, with a high of $469.00M and a low of $312.66M. This is -48.23% lower than Teva Pharmaceutical Industries's previous annual EBITDA (Dec 23) of $755.00M.
Teva Pharmaceutical Industries Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| Net Income | - | - | - | - | - | - | - | - | $461.00M | $80.00M | $-863.00M | $-239.00M | $-1.25B | $56.00M | - | $-973.00M | $-151.00M | $292.00M | $207.00M | $77.00M | $150.00M | $-4.47B | $140.00M | $69.00M | $80.00M | $-303.00M | $-671.00M | $-105.00M | $-3.25B | $-187.00M |
| Avg Forecast | $901.56M | $814.64M | $755.48M | $601.02M | $807.43M | $743.94M | $625.42M | $582.14M | $869.59M | $688.69M | $595.09M | $631.10M | $810.12M | $351.79M | $652.87M | $624.38M | $-149.91M | $319.81M | $199.47M | $71.78M | $138.10M | $-4.35B | $134.72M | $49.12M | $107.21M | $-319.32M | $-652.74M | $-101.38M | $-2.94B | $-154.07M |
| High Forecast | $915.10M | $826.87M | $766.84M | $610.05M | $819.57M | $791.17M | $634.81M | $590.88M | $985.53M | $767.72M | $604.02M | $640.59M | $822.29M | $422.15M | $652.87M | $642.84M | $-119.93M | $383.77M | $239.37M | $86.14M | $165.71M | $-3.48B | $161.66M | $58.94M | $128.66M | $-255.46M | $-522.19M | $-81.10M | $-2.35B | $-123.26M |
| Low Forecast | $874.63M | $790.31M | $732.93M | $583.08M | $783.32M | $673.09M | $606.73M | $564.74M | $834.81M | $632.25M | $577.31M | $612.25M | $785.93M | $281.43M | $652.87M | $604.01M | $-179.90M | $255.85M | $159.58M | $57.42M | $110.48M | $-5.22B | $107.77M | $39.29M | $85.77M | $-383.19M | $-783.28M | $-121.66M | $-3.53B | $-184.89M |
| Surprise % | - | - | - | - | - | - | - | - | 0.53% | 0.12% | -1.45% | -0.38% | -1.55% | 0.16% | - | -1.56% | 1.01% | 0.91% | 1.04% | 1.07% | 1.09% | 1.03% | 1.04% | 1.40% | 0.75% | 0.95% | 1.03% | 1.04% | 1.10% | 1.21% |
Teva Pharmaceutical Industries's average Quarter net income forecast for Mar 24 is $582.14M, with a range of $564.74M to $590.88M. TEVA's average Quarter net income forecast represents a 26.28% increase compared to the company's last Quarter net income of $461.00M (Dec 23).
Teva Pharmaceutical Industries SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| SG&A | - | - | - | - | - | - | - | - | $901.00M | $844.00M | $910.00M | $842.00M | $838.00M | $822.00M | - | $880.00M | $908.00M | $888.00M | $857.00M | $875.00M | $1.01B | $884.00M | $861.00M | $917.00M | $1.02B | $880.00M | $962.00M | $940.00M | $1.04B | $1.05B |
| Avg Forecast | $976.42M | $961.26M | $953.01M | $863.84M | $925.49M | $925.04M | $907.98M | $835.54M | $901.59M | $835.76M | $831.67M | $810.44M | $870.53M | $1.07B | $845.28M | $836.90M | $856.11M | $972.57M | $825.84M | $815.68M | $929.84M | $884.00M | $828.51M | $652.78M | $1.01B | $894.92M | $911.37M | $907.59M | $1.06B | $779.26M |
| High Forecast | $987.70M | $972.37M | $964.02M | $873.82M | $936.18M | $940.87M | $918.47M | $845.20M | $912.94M | $853.47M | $841.28M | $819.80M | $880.59M | $1.28B | $845.28M | $855.92M | $1.03B | $1.17B | $991.00M | $978.81M | $1.12B | $1.06B | $994.21M | $783.34M | $1.21B | $1.07B | $1.09B | $1.09B | $1.27B | $935.11M |
| Low Forecast | $953.99M | $939.18M | $931.12M | $843.99M | $904.23M | $897.90M | $887.12M | $816.35M | $878.88M | $802.80M | $812.56M | $791.82M | $850.53M | $855.86M | $845.28M | $815.89M | $684.89M | $778.06M | $660.67M | $652.54M | $743.87M | $707.20M | $662.81M | $522.22M | $806.56M | $715.93M | $729.09M | $726.07M | $844.15M | $623.41M |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.01% | 1.09% | 1.04% | 0.96% | 0.77% | - | 1.05% | 1.06% | 0.91% | 1.04% | 1.07% | 1.09% | 1.00% | 1.04% | 1.40% | 1.02% | 0.98% | 1.06% | 1.04% | 0.98% | 1.35% |
Teva Pharmaceutical Industries's average Quarter SG&A projection for Mar 24 is $835.54M, based on 3 Wall Street analysts, with a range of $816.35M to $845.20M. The forecast indicates a -7.27% fall compared to TEVA last annual SG&A of $901.00M (Dec 23).
Teva Pharmaceutical Industries EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| EPS | - | - | - | - | - | - | - | - | $0.41 | $0.07 | $-0.77 | $-0.21 | $-1.13 | $0.05 | - | $-0.88 | $-0.14 | $0.26 | $0.19 | $0.07 | $0.14 | $-4.08 | $0.13 | $0.06 | $0.07 | $-0.28 | $-0.61 | $-0.09 | $-3.15 | $-0.18 |
| Avg Forecast | $0.80 | $0.72 | $0.67 | $0.53 | $0.71 | $0.66 | $0.55 | $0.51 | $0.77 | $0.61 | $0.53 | $0.56 | $0.72 | $0.62 | $0.58 | $0.55 | $0.73 | $0.64 | $0.59 | $0.59 | $0.63 | $0.58 | $0.53 | $0.59 | $0.61 | $0.59 | $0.57 | $0.58 | $0.55 | $0.40 |
| High Forecast | $0.81 | $0.73 | $0.68 | $0.54 | $0.72 | $0.70 | $0.56 | $0.52 | $0.87 | $0.68 | $0.53 | $0.57 | $0.73 | $0.63 | $0.58 | $0.57 | $0.76 | $0.66 | $0.61 | $0.61 | $0.65 | $0.60 | $0.54 | $0.61 | $0.62 | $0.61 | $0.59 | $0.59 | $0.66 | $0.48 |
| Low Forecast | $0.77 | $0.70 | $0.65 | $0.51 | $0.69 | $0.59 | $0.54 | $0.50 | $0.74 | $0.56 | $0.51 | $0.54 | $0.69 | $0.60 | $0.58 | $0.53 | $0.71 | $0.62 | $0.57 | $0.57 | $0.61 | $0.56 | $0.51 | $0.57 | $0.59 | $0.57 | $0.55 | $0.56 | $0.44 | $0.32 |
| Surprise % | - | - | - | - | - | - | - | - | 0.53% | 0.12% | -1.47% | -0.38% | -1.58% | 0.08% | - | -1.60% | -0.19% | 0.40% | 0.32% | 0.12% | 0.22% | -7.01% | 0.25% | 0.10% | 0.12% | -0.47% | -1.07% | -0.15% | -5.73% | -0.45% |
According to 3 Wall Street analysts, Teva Pharmaceutical Industries's projected average Quarter EPS for Mar 24 is $0.51, with a low estimate of $0.50 and a high estimate of $0.52. This represents a 25.32% increase compared to TEVA previous annual EPS of $0.41 (Dec 23).
Teva Pharmaceutical Industries Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TLRY | Tilray Brands | $1.81 | $7.91 | 337.02% | Buy |
| CGC | Canopy Growth | $4.89 | $14.47 | 195.91% | Hold |
| ELAN | Elanco Animal Health | $14.29 | $25.83 | 80.76% | Buy |
| SNDL | SNDL | $2.21 | $3.95 | 78.73% | Hold |
| LFCR | Lifecore Biomedical | $5.08 | $8.00 | 57.48% | Buy |
| CRON | Cronos Group | $2.26 | $3.43 | 51.77% | Hold |
| BHC | Bausch Health Companies | $7.18 | $10.20 | 42.06% | Hold |
| CTLT | Catalent | $60.35 | $74.30 | 23.12% | Hold |
| ZTS | Zoetis | $195.71 | $227.71 | 16.35% | Buy |
| VTRS | Viatris | $11.82 | $13.75 | 16.33% | Hold |
| TEVA | Teva Pharmaceutical Industries | $17.85 | $19.17 | 7.39% | Buy |
| ACB | Aurora Cannabis | $5.96 | $5.92 | -0.67% | Hold |
| HLN | Haleon | $10.65 | $9.15 | -14.08% | Buy |
TEVA Forecast FAQ
Is Teva Pharmaceutical Industries a good buy?
Yes, according to 8 Wall Street analysts, Teva Pharmaceutical Industries (TEVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of TEVA's total ratings.
What is TEVA's price target?
Teva Pharmaceutical Industries (TEVA) average price target is $19.17 with a range of $10 to $26, implying a 7.39% from its last price of $17.85. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Teva Pharmaceutical Industries stock go up soon?
According to Wall Street analysts' prediction for TEVA stock, the company can go up by 7.39% (from the last price of $17.85 to the average price target of $19.17), up by 45.66% based on the highest stock price target, and down by -43.98% based on the lowest stock price target.
Can Teva Pharmaceutical Industries stock reach $30?
TEVA's average twelve months analyst stock price target of $19.17 does not support the claim that Teva Pharmaceutical Industries can reach $30 in the near future.
What is Teva Pharmaceutical Industries's current price target trend?
2 Wall Street analysts forecast a $24.5 price target for Teva Pharmaceutical Industries (TEVA) this month, up 37.25% from its last price of $17.85. Compared to the last 3 and 12 months, the average price target increased by 28.85% and increased by 17.09%, respectively.
What are Teva Pharmaceutical Industries's analysts' financial forecasts?
Teva Pharmaceutical Industries's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $16.05B (high $16.26B, low $15.66B), average EBITDA is $3.59B (high $3.71B, low $3.43B), average net income is $2.76B (high $2.84B, low $2.63B), average SG&A $3.59B (high $3.64B, low $3.51B), and average EPS is $2.44 (high $2.5, low $2.32). TEVA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $16.77B (high $16.96B, low $16.38B), average EBITDA is $4.35B (high $4.4B, low $4.25B), average net income is $3.07B (high $3.12B, low $2.98B), average SG&A $3.75B (high $3.8B, low $3.67B), and average EPS is $2.71 (high $2.75, low $2.63).
Did the TEVA's actual financial results beat the analysts' financial forecasts?
Based on Teva Pharmaceutical Industries's last annual report (Dec 2023), the company's revenue was $15.85B, beating the average analysts forecast of $15.09B by 4.99%. Apple's EBITDA was $433M, missing the average prediction of $3.33B by -87.00%. The company's net income was $-559M, missing the average estimation of $2.78B by -120.08%. Apple's SG&A was $3.5B, beating the average forecast of $3.38B by 3.51%. Lastly, the company's EPS was $-0.5, missing the average prediction of $2.46 by -120.34%. In terms of the last quarterly report (Dec 2023), Teva Pharmaceutical Industries's revenue was $4.46B, beating the average analysts' forecast of $4.03B by 10.69%. The company's EBITDA was $755M, missing the average prediction of $1.04B by -27.69%. Teva Pharmaceutical Industries's net income was $461M, missing the average estimation of $869.59M by -46.99%. The company's SG&A was $901M, missing the average forecast of $901.59M by -0.07%. Lastly, the company's EPS was $0.41, missing the average prediction of $0.768 by -46.58%